Guided Therapeutics

Guided Therapeutics EBITDA per Share

The EBITDA per Share of Guided Therapeutics (GTHP) as of Nov 14, 2026 is -0.03 USD. In the previous year, EBITDA per Share was -0.03 USD — a change of -14.93% (higher).

EBITDA per Share

-0.03USD

YoY

-14.93%

Last updated:

EBITDA per Share of Guided Therapeutics is 2025 -0.03 USD. EBITDA per Share of Guided Therapeutics was 2024 -0.03 USD. It decreases by -14.93% higher compared to the previous year.

The Guided Therapeutics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.58 USD
Jan 1, 2019
-0.28 USD
Jan 1, 2020
-0.08 USD
Jan 1, 2021
-0.17 USD
Jan 1, 2022
-0.07 USD
Jan 1, 2023
-0.06 USD
Jan 1, 2024
-0.03 USD
Jan 1, 2025
-0.03 USD
The Guided Therapeutics EBITDA per Share history
YEAREBITDA per ShareYoY
-0.03USD-14.93%
-0.03USD-49.35%
-0.06USD-6.84%
-0.07USD-60.30%
-0.17USD+115.74%
-0.08USD-71.64%
-0.28USD-51.32%
-0.58USD-98.85%
-50.38USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics, Inc. develops medical devices focused on cancer detection using biophotonics. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device for cervical cancer screening and triage. LuViva analyzes reflected and fluorescent light after scanning the cervix with light, offering an alternative to conventional tests. The firm targets healthcare providers and clinics seeking point-of-care solutions for cervical cancer detection. LuViva is designed for two main applications: as a screening tool for early detection of cervical cancer and precancers, and as a triage method to reduce unnecessary follow-up procedures. The company focuses on selling and marketing this device to medical facilities, emphasizing its painless, non-invasive nature and point-of-care functionality. Guided Therapeutics conducts limited clinical studies using its biophotonic technology to support the device's efficacy. The business model centers on the commercialization of LuViva, with the company developing prototypes and conducting clinical studies to validate its biophotonic detection method. Guided Therapeutics aims to position LuViva as a standard in cervical cancer screening, targeting healthcare providers who prioritize non-invasive, efficient diagnostic tools. The firm's revenue comes from the sale of LuViva devices and related services to medical institutions. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

EBITDA per Share of Guided Therapeutics is -0.03 USD in 2025.

EBITDA per Share of Guided Therapeutics changed from -0.03 USD to -0.03 USD, representing a -14.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Guided Therapeutics

All Key Metrics — Guided Therapeutics